Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation

Journal of Clinical Pharmacology

Volumn 37, Issue 10, 1997, Pages 893-903

  Möllmann, Helmut ^d   Derendorf, Hartmut ^a   Barth, Jürgen ^b   Meibohm, Bernd ^a   Wagner, Melanie ^b   Krieg, Michael ^b   Weisser, Heike ^b   Knöller, Jürgen ^c   Möllmann, Anja ^d   Hochhaus, Günther ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Focus IP GmbH   (Germany)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUNISOLIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG ACTIVITY; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; NORMAL HUMAN; PREDICTION; RECEPTOR AFFINITY; SYSTEMIC CIRCULATION; TANDEM MASS SPECTROMETRY;

EID: 9844247984     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04263.x     Document Type: Article

References (30)

1. Dry J, Sors C, Gervais P, van Straaten L, Perrin Fayolle M, Paramelle B: A comparison of flunisolide inhaler and beclomethasone dipropionate inhaler in bronchial asthma. J Int Med Res 1985;13:289-293.
2. Slavin RG, Izu AE, Bernstein IL, Blumenthal MN, Bolin JF, Ouellette JJ, et al.: Multicenter study of flunisolide aerosol in adult patients with steroid-dependent asthma. J Allergy Clin Immunol 1980;66:379-385.
3. Meltzer EO, Kemp JP, Orgel HA, Izu AE: Flunisolide aerosol for treatment of severe, chronic asthma in steroid-independent children. Pediatrics 1982;69:340-345.
4. Orgel HA, Meltzer EO, Kemp JP: Flunisolide aerosol in treatment of steroid-dependent asthma in children. Ann Allergy 1983;51:21-25.
5. Hochhaus G, Möllmann HW: Binding affinities of rimexolone (ORG 6216), flunisolide and their putative metabolites for the glucocorticoid receptor of human synovial tissue. Agents Actions 1990;30:377-380.
6. Chaplin MD, Cooper WC, Segre EJ, Oren J, Jones RE, Nerenherg C: Correlation of flunisolide plasma levels to eosinopenic response in humans. J Allergy Clin Immunol 1980;65:445-453.
7. Chaplin MD, Rooks Wd, Swenson EW, Cooper WC, Nerenberg C, Chu NI: Flunisolide metabolism and dynamics of a metabolite. Clin Pharmacol Ther 1980;27:402-413.
8. Derendorf H, Hochhaus G, Möllmann H, Barth J, Krieg M, Tunn S, et al.: Receptor-Based Pharmacokinetic-Pharmacodynamic Analysis of Corticosteroids. J. Clin Pharmacol 1993;33:115-123.
9. Rohatagi S, Hochhaus G, Möllmann H, Barth J, Galia E, Erdmann M. et al.: Pharmacokinetic and Pharmacodynamic Evaluation of Triamcinolone Acetonide after Intravenous, Oral, and Inhaled Administration. J. Clin. Pharmacol 1995;35:1187-1193.
10. Gibaldi M: Biopharmaceutics and Clinical Pharmacokinetics. 4th Edition ed. 1991, London: Lea and Febiger.
11. Derendorf H, Moellmann H, Barth J, Moellmann C, Tunn S, Krieg, M: Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol 1991;31:473-476.
12. Rohatagi S, Bye A, Mackie AE, Derendorf H: Mathematical modeling of cortisol circadian rhythm and cortisol suppression. Eur J Pharm Sci 1996;(in press).
13. Akaike A: Posterior probabilities for choosing a regression model. Annals of the Instistute of Mathematical Statistics 1978;30:9-14.
14. Thorsson L, Edsbacker S, Conradson TB: Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994;7:1839-1844.
15. Derendorf H, Hochhaus G, Rohatagi S, Möllmann H, Barth J, Erdmann M: Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 1995;35:302-305.
16. Zaborny BA, Lukacsko P, Barinov-Colligon I, Ziemniak JA: Inhaled corticosteroids in asthma: a dose-proportionality study with triamcinolone acetonide aerosol. J Clin Pharmacol 1992;32:463-469.
17. Hochhaus G: PK/PD Based Assessment of Pulmonary Effects and Systemic Side Effects After Inhalation. Pharm Res 1995;12 Suppl.:314.
18. Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R: Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982;63(Suppl. 122):86-95.
19. Mackie AE, Ventresca GP, Fuller RW, Bye A: Pharmacokinetics of intravenous fluticasone proprionate in healthy volunteers. Br J Clin Pharmacol 1996;41:539-542.
20. Johnson M: Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy ClinImmunol 1996;97:169-176.
21. Möllmann H, Hochhaus G, Rohatagi S, Barth J, Derendorf H: Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone. Pharm Res 1995;12:1096-1100.
22. Hochhaus G, Möllmann H, Barth J: Glucocorticoids for intra-articular therapy: Pharmacodynamic characterization via receptor binding studies. Akt Rheumatol 1990;15:66-69.
23. Hochhaus G, Möllmann H: Binding affinities of rimexelone (ORG 6216), flunisolide and their metabolites for the glucocorticoid receptor of human synovial tissue. Agents and Actions 1990;30:377-380.
24. Wuerthwein G, Rehder S, Rohdewald P: Lipophilicity and receptor affinity of glucocorticoids. Pharm Ztg Wiss 1992; 137:161-165.
25. Corren J, Rachelefsky G, Wand G: Effects of high dose inhaled corticosteroids on cortisol secretion: Comparison of beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate, and triamcinolone acetonide in healthy volunteers, submitted.
26. Tomlinson RV, Runkel R, Chaplin MD, Bowen L, Kanagy J, Chu N: In vitro studies on the binding of cloprednol to human plasma proteins. J Steroid Biochem 1982;16:75-80.
27. Rohatagi S, Bye A, Falcoz C, Mackie AE, Meibohm B, Moellmann H, Derendorf, H: Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol 1996;36:938-941.
28. Dahlberg E, Thalen A, Brattsand R, Gustafsson J-A, Johansson U, Roemke K, et al.: Correlation between chemical structure, Receptor binding, and biological activity of some novel, highly active, 16α, 17α-acetal-substituted-glucocorticoids. Mol Pharmacol 1983;25:70-78.
29. Suarez S, Gonzalez-Rothi R, Hochhaus G: The effect of dose and release rate on pulmonary targeting of glucocorticoids using liposomes as a model dosage form. Pharm Res 1996;13: S157.
30. Wiessmann KJ, Trautmann M: Fluticasone propionate (500 mg daily) and flunisolide (1000 mg daily) in the treatment of steroid-naïve patients with moderate asthma. Eur Respir J 1994;7(Suppl. 18): 383S.